James Feliciano, the country manager for Abbevie Inc, who also heads the American lobby PhRMA in Japan. Japan's three major pharmaceutical lobbies have joined for the first time in urging reforms to the government's drug-pricing system to avoid losing out on investment and new drugs.© Thomson Reuters
quote of the day
The policy environment in Japan has become increasingly unpredictable and challenging. The Japanese market is losing its attractiveness.
©2022 GPlusMedia Inc.